Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine Mueller

Showing results (181-190 of 223) with videos related to

Pageof 23
Sort By:
Neuro-Oncology|October 11, 2017
Pediatric low-grade gliomas: next biologically driven stepsDavid T W Jones, Mark W Kieran, Eric Bouffet, et al.
Nature Medicine|April 29, 2020
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumorsJohanna Theruvath, Elena Sotillo, Christopher W Mount, et al.
Neuro-Oncology|February 9, 2022
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline gliomaEvan Cantor, Kyle Wierzbicki, Rohinton S Tarapore, et al.
Nature Communications|January 2, 2025
Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade gliomaAnahita Fathi Kazerooni, Adam Kraya, Komal S Rathi, et al.
Journal of Neuro-Oncology|August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.
Neuro-Oncology|September 30, 2016
Pediatric low-grade gliomas: implications of the biologic eraRoger J Packer, Stephan Pfister, Eric Bouffet, et al.
Neuro-Oncology Advances|January 6, 2022
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine gliomaRyan J Duchatel, Abdul Mannan, Ameha S Woldu, et al.
Pediatric Blood & Cancer|June 14, 2021
Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinomaRichard T Graham, Mohammad H Abu-Arja, Joseph R Stanek, et al.
Neuro-Oncology|May 14, 2024
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma CoalitionPatricia O'Hare, Tabitha Cooney, Peter de Blank, et al.
The Journal of Clinical Investigation|July 1, 2020
Everolimus improves the efficacy of dasatinib in PDGFRα-driven gliomaZachary Miklja, Viveka Nand Yadav, Rodrigo T Cartaxo, et al.
Pageof 23

Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
Neuro-Oncology|October 11, 2017
Pediatric low-grade gliomas: next biologically driven stepsDavid T W Jones, Mark W Kieran, Eric Bouffet, et al.
Nature Medicine|April 29, 2020
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumorsJohanna Theruvath, Elena Sotillo, Christopher W Mount, et al.
Neuro-Oncology|February 9, 2022
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline gliomaEvan Cantor, Kyle Wierzbicki, Rohinton S Tarapore, et al.
Nature Communications|January 2, 2025
Multiparametric MRI along with machine learning predicts prognosis and treatment response in pediatric low-grade gliomaAnahita Fathi Kazerooni, Adam Kraya, Komal S Rathi, et al.
Journal of Neuro-Oncology|August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.
Neuro-Oncology|September 30, 2016
Pediatric low-grade gliomas: implications of the biologic eraRoger J Packer, Stephan Pfister, Eric Bouffet, et al.
Neuro-Oncology Advances|January 6, 2022
Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine gliomaRyan J Duchatel, Abdul Mannan, Ameha S Woldu, et al.
Pediatric Blood & Cancer|June 14, 2021
Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinomaRichard T Graham, Mohammad H Abu-Arja, Joseph R Stanek, et al.
Neuro-Oncology|May 14, 2024
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma CoalitionPatricia O'Hare, Tabitha Cooney, Peter de Blank, et al.
The Journal of Clinical Investigation|July 1, 2020
Everolimus improves the efficacy of dasatinib in PDGFRα-driven gliomaZachary Miklja, Viveka Nand Yadav, Rodrigo T Cartaxo, et al.
Pageof 23